To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Göttingen, Göttingen, Germany.
Laboratory of Flow Cytometry, Centre of Postgraduate Medical Education, Warsaw, Poland.
Dept. of Anesthesiology and Intensive Care Medicine & Center for Sepsis Control and Care (CSCC), Jena University Hospital-Friedrich Schiller University, Am Klinikum 1, Jena, Germany; Center for Clinical Studies, Jena University Hospital, Jena, Germany.
Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Infectious Diseases.ORCID iD: 0000-0003-3921-4244
Show others and affiliations
2021 (English)In: EBioMedicine, E-ISSN 2352-3964, Vol. 66, article id 103291Article, review/survey (Refereed) Published
Abstract [en]

Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treatment practices. We also highlight areas of improvement for animal studies in order to elevate their translational utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and strengthening the synergy between the preclinical and clinical domains is pivotal.

Place, publisher, year, edition, pages
Elsevier, 2021. Vol. 66, article id 103291
Keywords [en]
Animal model, COVID-19, Clinical trial, Pandemic, Pre-clinical research, Vaccine
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:oru:diva-90965DOI: 10.1016/j.ebiom.2021.103291ISI: 000647447600005PubMedID: 33813139Scopus ID: 2-s2.0-85103643396OAI: oai:DiVA.org:oru-90965DiVA, id: diva2:1543803
Note

Funding Agencies:

Science Foundation Ireland 20/COV/0038

CIBERESUCICOVID (ISCII grant)  

Charite -Universitatsmedizin Berlin  

BIH  

FrameWork 7 program HemoSpec  

Horizon2020 Marie-Curie Project European Sepsis Academy  

Horizon 2020 European Grant ImmunoSep  

Poland National Science Centre UMO-2020/01/0/NZ6/00218

SARTORIUS AG Lung Research  

Available from: 2021-04-13 Created: 2021-04-13 Last updated: 2024-01-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Cajander, Sara

Search in DiVA

By author/editor
Cajander, Sara
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
EBioMedicine
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 43 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf